Announcements Trials
Browse Landscape

Status

No longer available 2Approved for marketing 2

Sponsor Class

OTHER 4

Study Type

Interventional 247Observational 18Expanded_access 4

Sponsor

Cancer Type

Genitourinary 4Head & Neck 1

Conditions

Prostatic Neoplasms 4

Interventions

gallium 68 PSMA-11 4Magnetic Resonance Spectroscopy 4Abiraterone Acetate 3carbon-11 acetate 2Prednisone 2Prednisolone 2Axitinib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zenocutuzumab 1ulixertinib 1trametinib 1tempol 1tazemetostat 1talazoparib 1radium Ra 223 dichloride 1pegilodecakin 1omburtamab I-131 1niraparib 1neratinib 1motexafin gadolinium 1enfortumab vedotin 1dodecyl maltoside 1bicalutamide 1bemarituzumab 1balstilimab 1atezolizumab 1apalutamide 1TEMPOL-H 1Suspensions 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × Magnetic Resonance Spectroscopy × Genitourinary × Clear all
NCT04809584 2024-12-19

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Stanford University

Approved for marketing
Genitourinary

Prostatic Neoplasms

NCT05002465 2023-09-11

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

University of Texas Southwestern Medical Center

No longer available
Genitourinary

Prostatic Neoplasms

NCT03501940 2022-01-21

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Stanford University

No longer available
Genitourinary

Prostatic Neoplasms

NCT04377152 2021-03-01

Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

University of California, San Francisco

Approved for marketing
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡